| Download the amazing global Makindo app: ✅ Means NICE/National Guidelines 2026 compliant Android | Apple | |
|---|---|
| MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer. |
Related Subjects: |Diabetes Mellitus: Basics |Type 1 Diabetes Mellitus | Type 2 Diabetes Mellitus | Type 3c Diabetes Mellitus |Insulin Physiology |Gestational Diabetes |HbA1c |Hyperglycaemic Hyperosmolar State (HHS) |Diabetic Nephropathy |Diabetic Retinopathy |Diabetic Neuropathy |Diabetic Amyotrophy |Maturity Onset Diabetes of the Young (MODY) |Diabetes: Complications |Hypoglycaemia |Diabetic Ketoacidosis (DKA) Adults |Alcoholic Ketoacidosis |Euglycaemic Ketoacidosis (euDKA) with SGLT2 Inhibitors |Causes of Ketoacidosis |Gold Score: Hypoglycaemia Awareness in Type 1 Diabetes
👁️ Diabetic retinopathy is largely preventable: tight glycaemic control, BP and lipids slow microvascular damage; timely laser/anti-VEGF preserves sight. In the UK, routine annual screening from age 12 (NHS DES) catches asymptomatic disease early.
A 58-year-old with T2D (12 yrs), HbA1c 74 mmol/mol, BP 154/92, reports mild central blur. Screening photo shows hard exudates within 1DD of the fovea and thickening on OCT. ✅ M1 maculopathy → refer urgently for anti-VEGF; tighten BP and glucose; start/optimise statin and ACEi.
If you remember just three things for viva: duration drives risk, VEGF links ischaemia to oedema/neovascularisation, and R3/M1 need urgent eyes-on. Everything else is risk-factor medicine.